Skip to content
PeptideAgent

P21 regulatory status

Current status of P21 in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of P21?

Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 22, 2026
FDA and compounding
P21 has never been nominated to or reviewed for the FDA 503A or 503B bulks lists and does not appear in any category on the FDA Category 2 page (current as of April 22, 2026). It is not a component of any approved drug, so a 503A pharmacy has no lawful basis to compound it. It is not an FDA approved drug.
WADA
WADA prohibited
Access path
  1. Not legally available for human use in the United States.
  2. Not an FDA approved drug and not compoundable under 503A or 503B.
  3. Products labeled research use only are not lawful for human use and are not verified for purity.

Full P21 page: evidence, dosing in the literature, and sources

How has the status of P21 changed over time?

No dated regulatory event has been recorded for P21. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for P21 and the source of each dated event.

  1. [1]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list and withdrawn nominations, current as of April 22, 2026)FDA, 2026
  2. [2]FDA: Compounding and the FDA, questions and answersFDA, 2026
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026